NCT02875847View on ClinicalTrials.gov

Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Irritable Bowel Syndrome (IBS)
Interventions
DIETARY_SUPPLEMENT

HMO1

DIETARY_SUPPLEMENT

HMO2

DIETARY_SUPPLEMENT

Dextropur

Trial Locations (1)

SE-413 35

SU Sahlgrenska, Department of Internal Medicine, Gothenburg

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

lead

Glycom A/S

INDUSTRY

NCT02875847 - Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients | Biotech Hunter | Biotech Hunter